Drug Trial Radar · NCT06504147
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
114
Planned (sponsor's estimate)
Start
Jun 15, 2024
Primary completion
Feb 29, 2028
Study completion Feb 28, 2031
Sponsor
- Lead sponsor
- Oncoinvent Solutions ASIndustry
- Sponsor type
- Industry
- First posted
- Jul 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, controlled, randomised, parallel assignment, open label, multicentre study to evaluate efficacy and safety of a single intraperitoneal injection of Radspherin® in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are HR proficient and scheduled to undergo NACT and IDS. The study will be conducted in 2 parts; first, a Safety Lead-in Cohort will be recruited followed by the randomised part of the study. For both parts of the study, patients must be scheduled to undergo NACT and IDS and complete resection to no residual tumour (R0) should be deemed to be achievable during diagnostic work-up. Patients in both parts of the study will undergo the same procedures and assessments.
Conditions
- Peritoneal Carcinomatosis
- Ovarian Cancer
Interventions
RadspherinDrug
Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survivalTime frame: 24 months
Locations
10 sites in 6 countries. Site status is shown where the registry gives one.
Moffitt Cancer Center
Tampa, Florida · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, Italy · Recruiting
The Norwegian Radiumhospital
Oslo, Norway · Recruiting
Hospital Universitari de Bellvitge
Barcelona, Spain · Recruiting
Clinica Universidad de Navarra
Madrid, Spain · Recruiting
Clinica Universidad de Navarra
Pamplona, Spain · Recruiting
Hospital Universitari i Politècnic La Fe
Valencia, Spain · Recruiting
Imperial College Healthcare NHS Trust
London, United Kingdom · Recruiting
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.